Industry News
Biotechnology Industry News
Eli Lilly is paying $100 million…
Eli Lilly is paying $100 million upfront for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection.
A new entrant in the race to…
A new entrant in the race to shepherd antibodies for Alzheimer’s disease across the blood-brain barrier has emerged. Korsana Biosciences has catapulted out of stealth with $175 million and designs for a 2027 clinical debut.
Boehringer Ingelheim is discarding…
Boehringer Ingelheim is discarding an inhaled gene therapy designed to treat cystic fibrosis after terminating a phase 1/2 trial.
Japan-based cell therapy company…
Japan-based cell therapy company Innovacell is planning to end a drought of biotech IPOs on the Tokyo Stock Exchange next week, the business’ CEO has confirmed.
Cyrano Therapeutics is savoring a…
Cyrano Therapeutics is savoring a phase 2 victory. With the Flavor study hitting its primary endpoint, the biotech is preparing to take its treatment for persistent smell loss into phase 3 in the second half
Compass Pathways has reported…
Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the biotech’s share price up 30% and teeing up talks about filing for approval.
As Sanofi attempts to bounce back…
As Sanofi attempts to bounce back from a tough year of clinical readouts, the French pharma has touted longer-term phase 2 data for its bowel disease bet as showing the Teva-partnered prospect remains a “key
Gilead Sciences has secured…
Gilead Sciences has secured another synthetic lethal therapy, handing $80 million upfront for the global rights to a clinic-ready cancer drug from China’s Genhouse Bio.
The FDA has rejected a rare blood…
The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that been granted expedited review through a newly launched priority voucher program.
Just as a disciplined soccer…
Just as a disciplined soccer player might pass on a hopeful shot in favor of better chance later on, the biopharma venture capital market reflected a preference for de-risked assts over platforms and predicted a
After a string of high-profile…
After a string of high-profile regulatory rebukes, Biohaven’s CEO believes red tape is getting in the way of patient well-being, particularly for those with rare diseases.
With sales of Immunocore’s…
With sales of Immunocore’s melanoma medicine steadily ticking up, an expanded label likely down the line and a longtime colleague no longer at her side, CEO Bahija Jallal, Ph.D., is mixing caution with ambition as
Messenger RNA specialist Moderna’s…
Messenger RNA specialist Moderna's R&D spend sunk by nearly a third last year, a drop attributed in part to the wind-down of major phase 3 respiratory trials.
Ultragenyx’s employees were…
Ultragenyx's employees were already braced for changes as the biopharma considered how to rebound from a pair of failed late-stage brittle bone disease trials.
Sanofi is replacing CEO Paul…
Sanofi is replacing CEO Paul Hudson with Merck KGaA leader Belén Garijo, M.D., Ph.D., after a series of R&D setbacks at the French pharma. Hudson will end his six-year run at Sanofi’s helm Feb. 17,
After scrapping one portion of the…
After scrapping one portion of the trial, Lundbeck’s intravenous monoclonal antibody has met the main goal of a phase 2b migraine prevention study, with multiple doses of the experimental treatment tied to a change in
Just months after laying off a…
Just months after laying off a quarter of its workforce to fund a phase 2 study of its bloodstream infection preventive treatment, Seres Therapeutics is pausing that investment and sending more employees to the exits.
BridgeBio is hoping that…
BridgeBio is hoping that infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in a form of dwarfism in children.
For all of the groundbreaking…
For all of the groundbreaking advancements in cancer treatment over the last decades, the first step for tackling almost all solid tumors is still surgery. If the cancer comes back, medicines like immunotherapies can then
Massachusetts’ largest life…
Massachusetts’ largest life science employer has put more than 630,000 square feet of office space on the sublease market as part of efforts to consolidate the Japanese company’s U.S. corporate hub at a new Cambridge